Key Segmentation:
By Product
-
Diagnostic Tests
-
Diagnostic Devices
-
Genetic and Genomic Panels
By Technology
-
Immunoassays
-
Molecular Diagnostics
-
Imaging
-
AI-Enabled Analytics
By Application
-
Breast Cancer Testing
-
Cervical Cancer Testing
-
Prenatal and Fertility Testing
-
Infectious Disease Testing
By End User
-
Hospitals and Diagnostic Centers
-
Home Care
-
Others
Regional Coverage:
North America
-
United States
-
Canada
Europe
-
Germany
-
United Kingdom
-
France
-
Italy
-
Spain
-
Russia
-
Poland
-
Rest of Europe
Asia Pacific
-
China
-
India
-
Japan
-
South Korea
-
Australia
-
ASEAN Countries
-
Rest of Asia Pacific
Middle East & Africa
-
UAE
-
Saudi Arabia
-
Qatar
-
South Africa
-
Rest of Middle East & Africa
Latin America
-
Brazil
-
Argentina
-
Mexico
-
Colombia
-
Rest of Latin America
Available Customization:
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
-
Detailed Volume Analysis
-
Criss-Cross segment analysis (e.g. Product X Application)
-
Competitive Product Benchmarking
-
Geographic Analysis
-
Additional countries in any of the regions
-
Customized Data Representation
-
Detailed analysis and profiling of additional market players
Frequently Asked Questions
Key players in the market include Hologic, Roche, Abbott, Becton Dickinson, Siemens Healthineers, and Quest Diagnostics, among others.
Key opportunities include home self-collection kits and early detection technologies such as artificial intelligence imaging and multi-cancer blood tests.
National screening programs and technology advances such as self-collection and noninvasive prenatal testing are the major growth factors.
The Diagnostic Tests segment dominated the market in 2025 with approximately 54.21% share, as screening and monitoring programs generate recurring, high volume demand.
North America dominated the market in 2025 with approximately 37.33% share, supported by organized screening, broad insurance coverage for preventive tests, and fast adoption of new technology.